Panel Discussion on ‘Next-gen oral dosage forms’ | FDD Conclave 2022

Panelists in this video:
+ Dr C Muthulingam, VP-Formulations, Mankind Pharma
+ Dr N Ravikumar, EVP – FR&D, MSN Laboratories
+ Dr Umesh Setty, Sr VP-FR&D, Caplin Point Laboratories
+ Dr Meka Lingam, VP- FR&D, Lee Pharma

Moderator:
+ Vinod Arora, Principal Advisor, Institute of Good Manufacturing Practices India (IGMPI)

Key Highlights:
+ Digitalisation, patient centricity, the need for personalised medicines, and emerging technologies are transforming FR&D of oral dosage forms: Vinod Arora, Principal Advisor, Institute of Good Manufacturing Practices India (IGMPI)

+ In the last 10 years, technology has changed hugely. In the next 10 years, 3D printing will make it possible to develop next-generation oral dosage forms: Dr C Muthulingam, VP-Formulations, Mankind Pharma

+ Digitalisation can add value to the FR&D process, enable patient compliance and product differentiation, and enhance the quality and compliance of medications: Ravikumar N, EVP – FR&D, MSN Laboratories

+ With 3D printing technology we cannot do mass production: Dr Umesh Setty, Sr VP – FR&D, Caplin Point Laboratories

+ Technologies like precipitation inhibitors and new age polymers are mitigating risks and challenges in self-emulsifying systems and making them more efficient and effective: Dr Meka Lingam, VP – FR&D, Lee Pharma